PDCD1 and neoplasm: Bifunctional CAR-T cells targeting c-Met and blocking programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) binding exerted stronger solid tumor antitumor activity and T cell persistence than single-target CAR-T cells in a tumor cell xenograft model (Yuan et al., 2021).